Loading organizations...
Pathware develops the Bioptic platform, a digital pathology system integrating computational microscopy and artificial intelligence. It provides real-time, on-site biopsy quality assessment, generating whole slide images and delivering key tissue metrics to clinicians. The platform optimizes pathology workflows, reduces inadequate samples, and enhances diagnostic accuracy at the point of care.
Jaron Nix and Michael Moore co-founded Pathware, incorporating in 2018. Michael Moore’s personal experiences with delayed cancer diagnoses provided the core insight. Recognizing inefficiencies and patient anxieties from inadequate biopsy samples, the founders created an immediate, accurate quality assessment solution, improving diagnostic pathways.
The Bioptic platform serves clinicians and pathologists, streamlining assessment and integrating data into electronic health records. Pathware’s vision is to improve healthcare through computational microscopy and AI, eliminating diagnostic delays. The company aims to reduce costs from inadequate biopsies, ensuring timely, confident diagnoses for patients.
Pathware has raised $7.0M across 1 funding round.
Pathware has raised $7.0M in total across 1 funding round.
Pathware is a MedTech company developing hardware and software solutions for real-time biopsy quality assessment in digital pathology.[1][2][5] Its flagship product, Bioptic™, is a cloud-based platform that evaluates biopsy sample quality on-site in minutes with over 90% certainty, reducing inadequate biopsies (20-25% of cases), repeat procedures, and unnecessary surgeries that cost the healthcare system $1.6B annually.[3][5] Pathware serves patients, pathologists, hospitals, and insurance companies by streamlining workflows, improving diagnostic accuracy, and cutting costs like $3,000 per repeat biopsy or $11,000 per unwarranted thyroidectomy.[2][5] Founded in 2017 and headquartered in Seattle, Washington, the company has raised $11.72M in Series A funding, with the latest $7M round three years ago, and remains in active growth at the Series A stage.[1]
Pathware emerged from a team of researchers from the University of Alabama and University of Michigan, who identified the high rate of inconclusive biopsies due to poor sample quality.[3] The idea gained traction through participation in accelerator programs, including NSF I-Corps in 2016, VentureWell's E-Team in 2017, ASPIRE Healthcare at TechTown in 2017, and OPEN Minds in 2018.[3] Originally known as MedKairos, the company was formally founded in 2017 in Seattle and received early investment from VentureWell in February 2019 alongside Valley Venture Mentors and Unity Point Health.[1][3] A pivotal leadership shift occurred with TJ Meyer appointed as CEO; he previously led marketing, strategy, and business development at Veran Medical Technologies, focusing on lung cancer diagnostics.[1] These milestones positioned Pathware to pursue FDA clearance for its integrated system.[1]
Pathware rides the wave of AI-driven digital pathology and point-of-care diagnostics, a trend accelerating with machine learning's ability to analyze tissue samples faster than human pathologists alone.[1][4] Timing is ideal amid rising biopsy volumes (2.7M fine-needle aspirates yearly) and healthcare pressures to cut costs amid labor shortages, where 92% of thyroid surgeries post-indeterminate biopsies prove unnecessary.[5] Market forces like FDA pushes for efficient MedTech and post-pandemic telehealth expansion favor on-site tools that minimize central lab bottlenecks.[1] Pathware influences the ecosystem by pioneering biopsy optimization, potentially setting standards for AI in histopathology and enabling earlier interventions in cancer care.[1][3]
Pathware is poised to disrupt diagnostics by securing FDA clearance for its full system, expanding its team, and scaling Bioptic™ adoption amid surging demand for AI pathology tools.[1] Trends like AI integration in MedTech and value-based care will propel growth, especially as inadequate biopsies drain billions—positioning Pathware to capture market share from slower lab-based rivals. Its influence may evolve from niche innovator to ecosystem leader, humanizing cancer journeys by slashing waits and waste, much like its origins humanized flawed biopsy workflows with real-time precision.[1][5]
Pathware has raised $7.0M in total across 1 funding round.
Pathware's investors include Level 8 Ventures, Austin Duke, David Johnson, James Watt, Monica Richter, Peter Faroni, Sidney Taurel, Steve Laczynski, Michael Weinmann, Solas BioVentures.
Pathware has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $7.0M Series A | Level 8 Ventures, Austin Duke | David Johnson, James Watt, Monica Richter, Peter Faroni, Sidney Taurel, Steve Laczynski, Michael Weinmann, Solas BioVentures |